Valiant Organics Presents Investor Presentation at 21st AGM
Valiant Organics Limited held its 21st AGM on September 29, 2026, presenting an investor presentation. The company is a leading global chlorophenol derivatives manufacturer and domestic PNA producer. FY26 revenue was ₹739 crore with a 13.64% EBITDA margin. Key revenue drivers include Hydrogenation and Ammonolysis chemistries, serving Dyes & Pigments, Agro Chemicals, and Pharma sectors.
This is a routine disclosure of an investor presentation shared at an AGM. It provides an update on the company's business overview and financial highlights but does not introduce significant new material information that would strongly impact the stock price.
The announcement is a factual disclosure of an investor presentation shared at the Annual General Meeting. It does not contain any new financial results or forward-looking statements that would indicate a positive or negative sentiment.
Valiant Organics Limited announced that the investor presentation made to the shareholders at the 21st Annual General Meeting held on Tuesday, September 29, 2026, has been attached for records.
The company highlighted its position as one of the largest chlorophenol derivatives manufacturers globally and a leading domestic PNA manufacturer. Valiant Organics serves a diversified client base across Pharmaceuticals, Dyes & Pigments, Agrochemicals, and specialty chemicals sectors, operating six manufacturing units across five locations with five Zero Liquid Discharge plants.
The presentation also detailed the company's financial performance, showing operating revenue of ₹739 crore and an EBITDA margin of 13.64% for FY26. Key chemistries driving revenue include Hydrogenation (48%), Ammonolysis (26%), Chlorination (20%), and Others (6%). The end-user industry breakdown shows Dyes & Pigments accounting for 45% of revenue, followed by Agro Chemicals (24%), Pharmaceuticals (21%), and Specialty Chemicals (10%).
Key strengths emphasized include a robust business model, domain knowledge, integrated operations, a widespread supply chain, strong customer relations, strategic plant locations, and a distinct product portfolio. The company also provided financial highlights for FY23-FY26, including operational revenue, EBITDA, PAT, ROCE, ROE, and Net Debt to Equity ratios.
What to do with a filing like this
Valiant Organics Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Valiant Organics Limited. Read the original for the full detail.